Minimum Data Set

1. Percentage of people with advanced HIV infection receiving ART
   • Numerator: Number of people receiving ART according to UNAIDS/WHO standards at the start of the year + number of people who started treatment in the last 12 months – number of people for whom treatment was stopped (including those who died)
   • Denominator: Number of people with advanced HIV disease (often estimated to be 15 percent of total number with HIV infection)
2. Number of drug regimens distributed each month
3. 12-month program retention rate
   • Numerator: Number of individuals who are still on treatment 12 months after beginning therapy
   • Denominator: All patients who are started on therapy over a given period of time
4. Percentage of adults on treatment who gain weight
   • Numerator: Percentage of adults who gain at least 10 percent body weight at month six after initiation of ART
   • Denominator: All patients who were started on ART who presented with weight loss or cachexia
   • Note: This number uses weight gain as a rough indicator for therapeutic success. As treatment is made available earlier in the course of disease this parameter may become less helpful. It also has less utility in centers where CD4 cell counts are available.
5. Survival rate
   • Numerator: Number of people still alive at 6 months, 12 months, and 24 months after initiation of ART
   • Denominator: Total number of individuals in treatment
6. Prevention of mother-to-child transmission
   • Numerator: Number of HIV-positive pregnant women who received ART for pMTCT
   • Denominator: Number of HIV-positive pregnant women who are offered ART

Additional useful programmatic data

1. Number of patients who are offered VCT
2. Percentage of patients who accept HIV testing
3. Proportion of HIV tests that are positive
4. Mean increase in CD4 cell count in patients on therapy
5. Percentage of HIV infected patients who are screened for STIs and TB, and number who complete treatment
6. Percentage of patients receiving social support (e.g., educational and nutritional assistance)
7. Number of HIV-positive patients receiving prophylaxis for opportunistic infections
8. Toxicities of ART
9. Number of patients switched from first-line therapy and reasons for change
10. Percentage of patients who have significant increase in CD4 cell count six months after initiation of therapy
11. Percentage of children who have a definitive diagnosis of HIV infection among all children whose mother received ART